Document:

EX-10.36

 Exhibit 10.36 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
  
 

 
 David A. Vallo 
 Senior Protect
Manager 
 MedImmune, LLC 
 One MedImmune Way 

Gaithersburg, MD 20878 
 USA 

Bellinzona, April 19, 2013 
 Re: Sub-License and Collaboration Agreement dated as of March 20, 2012 (“Agreement”) between MedImmune LLC (“MedImmune”) and Humabs BioMed SA (“Humabs”) 

Dear Mr. Vallo, 
 We hereby notify MedImmune of
Humabs’ agreement to extend the scope of the Research Project to work on Klebsiella, which has been elected as the Extra Target in accordance with Section 5.19.2 of the Agreement. 

In consideration of the generally increased research costs per FTE at Humabs, we submits to MedImmune the request to increase the amount of Research Funding
payments (Section 5.23.1.1. of the Agreement) from [***] of the Research Term. 
 Thank you for your time and cooperation. We also continue to look forward
to a successful collaboration with MedImmune. 
 Yours sincerely, 

/s/ Alcide Barberis 
 Alcide Barberis, PhD 

President and CEO 
 Humabs BioMed SA 

Via Mirasole 1 
 CH-6500
Bellinzona, Switzerland 
 [***]EX-10.37

 Exhibit 10.37 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 MedImmune Confidential 

AMENDMENT 2 TO SUB-LICENCE AND COLLABORATION AGREEMENT 

This Amendment (the “Amendment”) to the Sub-License and Collaboration Agreement dated March 20,
2012 (“Agreement”) is entered into effective as of the last date of signature (the “Amendment Effective Date”), by and between MedImmune, LLC, a Delaware limited liability company, with its principal executive
offices located at One MedImmune Way, Gaithersburg, MD 20878 (“MedImmune”) and Humabs BioMed SA. a limited company organized under the laws of Switzerland having its head office at Via Mirasloe 1, bellinzona CH-6500 Switzerland (“Humabs”). 
 Background 

WHEREAS, the parties desire extend the Research Term of the Agreement pursuant to the terms and conditions of the Agreement. 

NOW, THEREFORE, for valuable consideration, the sufficiency of which is acknowledged, the parties agree as follows: 

 

	1.	 Definitions. Unless otherwise defined in this Amendment, capitalized terms have the meanings set
forth in the Agreement. 

  

	2.	 Research Term. The Research Term of the Agreement is extended until [***] unless sooner
terminated in accordance with the termination provisions of the Agreement or extended by mutual written agreement of the Parties. 

  

	3.	 Full Force and Effect. Except as set forth in this Amendment, all terms and conditions of the
Agreement remain in full force and effect. 

  

	4.	 Counterparts. This Amendment may be executed in two or more counterparts, each of which will be
deemed an original and all of which will together be deemed to constitute one agreement. The Parties agree that the execution of this Amendment by industry standard electronic signature software and/or by exchanging PDF signatures shall have the
same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or relating to this Amendment, each Party hereby waives any right to raise any defense or waiver based upon execution of this Amendment by
means of such electronic signatures or maintenance of the executed agreement electronically. 

 The parties have executed this Amendment
to be effective as of the Amendment Effective Date. 

  

					
	Agreement Number: CW451495	  	1	  	

									
	MEDIMMUNE, LLC	 		 	HUMABS BIOMED SA
					
	By:	 	/s/ Ken Stover	 	    	 	By:	 	/s/ Alcide Barberis
	Name:	 	Ken Stover	 		 	Name:	 	Alcide Barberis
	Title:	 	Sr. Dir. Research	 		 	Title:	 	CEO
	Date:	 	27 April 2015	 		 	Date:	 	April 27, 2015
				
		 		 		 	HUMABS BIOMED SA
					
		 		 		 	By:	 	/s/ Davide Corti
		 		 		 	Name:	 	Davide Corti
		 		 		 	Title:	 	CSO
		 		 		 	Date:	 	April 27, 2015

  
 2.EX-10.38

 Exhibit 10.38 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 AMENDMENT NO. 3 TO SUB-LICENCE AND
COLLABORATION AGREEMENT 
 This Amendment No. 3 to Sub-Licence and Collaboration Agreement
(“Amendment No.3”) is effective as of 31 December 2015 (the “Amendment No.3 Effective Date”) by and between MedImmune, LLC, a Delaware limited liability company with a place of business at One MedImmune Way, Gaithersburg,
MD20878, United States (“MedImmune”) and Humabs BioMed SA, a limited company organized under the laws of Switzerland having its head office at Via Mirasloe 1, Bellinzona CH-6500, Switzerland (
“Humabs”). MedImmune and Humabs are each referred to herein as a “Party” and collectively as the “Parties”. 

WHEREAS, the Parties entered a Sub-Licence and Collaboration Agreement dated 20 March 2012, as
amended by letter dated 4 April 2013 and Amendment No.2 to Sub-Licence And Collaboration Agreement dated 27 April 2015 (collectively the “Agreement”); 

WHEREAS, the Parties wish to extend the Research Term of the Agreement. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the adequacy and sufficiency of which is hereby
acknowledged, the Parties agree that the Agreement is hereby amended as follows: 
  

	 	1.	 The Research Term of the Agreement is extended until [***], unless sooner terminated in accordance with the
termination provisions of the Agreement or extended by mutual written agreement of the Parties. 

  

	 	2.	 The Parties agree that MedImmune shall pay to Humabs [***] in respect of the activities to be conducted during
the additional 

 [***] set forth in Section 1 above. Payment of such sum shall be made in accordance
with clause 5.23.5 of the Agreement. 
  

	 	3.	 The activities to be conducted during the [***] set forth in Section 1 above shall be agreed pursuant to
Section 5 of the Agreement. 

  

	 	4.	 Capitalized terms used in this Amendment and not otherwise defined shall have the meanings set forth in the
Agreement. 

  

	 	5.	 Except for the modifications set forth above, the Agreement shall remain unchanged and in full force and
effect. 

  

	 	6.	 This Amendment may be executed in two or more counterparts, each of which will be deemed an original and all of
which will together be deemed to constitute one Amendment. The Parties agree that the execution of this Amendment by industry standard electronic signature software and/or by exchanging PDF signatures shall have the same legal force and effect as
the exchange of original signatures, and that in any proceeding arising under or relating to this Amendment, each Party hereby waives any right to raise any defense or waiver based upon execution of this Amendment by means of such electronic
signatures or maintenance of the executed Amendment electronically. 

  

					
	Agreement Number: CW474245	  	Page 1 of 2	  	/s/ FR   /s/DC

 IN WITNESS WHEREOF THE PARTIES SET THEIR NAMES HERETO TO BE IN EFFECT AND LEGALLY BINDING AS
OF THE AMENDMENT NO.3 EFFECTIVE DATE. 
  

									
	MEDIMMUNE, LLC	 		 	HUMABS BIOMED SA
					
	By:	 	 /s/ JoAnn Suzich 
	 	    	 	By:	 	 /s/ Filippo Riva

	Name:	 	JoAnn Suzich	 		 	Name:	 	Filipo Riva
	Title:	 	Vice President	 		 	Title:	 	CEO & CFO
	Date:	 	31 Dec 2015	 		 	Date:	 	12.23.2015
				
		 		 		 	HUMABS BIOMED SA
					
		 		 		 	By:	 	 /s/ Davide Corti 

		 		 		 	Name:	 	Davide Corti
		 		 		 	Title:	 	CSO
		 		 		 	Date:	 	12.23.2015

  

					
	Agreement Number: CW474245	  	Page 2 of 2EX-10.39

 Exhibit 10.39 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 AMENDMENT 4 TO SUB-LICENCE AND
COLLABORATION AGREEMENT 
 This Fourth Amendment (the “Amendment”) to the Sub-Licence and
Collaboration Agreement dated 20 March 2012, as amended (the “2012 Agreement”) is entered into and effective as of the last date of signature (the “Amendment Effective Date”), by and between: 

MedImmune, LLC, having a place of business at One MedImmune Way, Gaithersburg, MD 20878, USA (“MedImmune”); and 

Humabs BioMed SA, a limited company organized and existing under the laws of Switzerland, having its head office at Via Mirasole 1, Bellinzona CH-6500 Switzerland (“Humabs”). 
 MedImmune and Humabs may each be referred to herein individually as a
“Party” and collectively as the “Parties”. 
 Background 

 

	 	(A)	 WHEREAS, MedImmune and Humabs entered into the 2012 Agreement; 

 

	 	(B)	 WHEREAS, MedImmune and The Defense Advanced Research Projects Agency (“DARPA”) have entered into a
Technology Investment Agreement dated 31 March 2016 (the “DARPA Agreement”) concerning a research project entitled, OPTIMIZATION OF HUMAN B CELL LEAD
GENERATION PLATFORMS FOR MONOCLONAL ANTIBODIES AGAINST DRUG-RESISTANT BACTERIAL
INFECTIONS (“DARPA Research”); 

  

	 	(C)	 WHEREAS, MedImmune and Humabs intend to enter into a Subcontract Agreement following the Effective Date,
pursuant to which Humabs will become a subcontractor of MedImmune under the DARPA Agreement (“DARPA Subcontract”) in a form acceptable to both Parties; and 

 

	 	(D)	 WHEREAS, in recognition of the foregoing the Parties desire to amend certain terms of the 2012 Agreement to
accommodate the planned DARPA Research. 

 Terms and Conditions 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Amendment, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, MedImmune and Humabs, intending to be legally bound, hereby agree as follows: 
 1.
Definitions 
  

	 	1.1	 Any capitalised terms not separately defined in this Amendment shall have the meaning ascribed to them in the
2012 Agreement. 

  
 Page 1 of 8 

/s/FR  /s/DC 

 2. Amendment 

 

	 	2.1	 The Parties acknowledge that Klebsiella was accepted as an “Extra Target” by Humabs under
Section 5.19.2 of the 2012 Agreement pursuant to a letter from Humabs to MedImmune dated 19 April 2013, and consequently the Parties further acknowledge that the terms of the 2012 Agreement applicable to an Extra Target apply to
Klebsiella. Pursuant to Section 5.22, the provisions which apply to the Second Target and Second Target Products shall apply equally to the Extra Target and Biologics directed to such Extra Target including, without limitation, the payment
terms in clause 4.2.2 and 4.3.2. 

  

	 	2.2	 Pursuant to 5.22.2, a new definition shall be added as follows: 

“Additional Research Plan” means the description of work to be performed by the Parties in respect of the Extra Target as set
out in the Annex II to this Amendment and a copy of which will be included in the DARPA Subcontract . . 
  

	 	2.3	 Any references to the Research Plan in the 2012 Agreement shall also be deemed to include reference to the
Additional Research Plan. MedImmune shall not (i) consent or (ii) induce by its conduct and/or interactions with DARPA, any modifications to the DARPA Agreement and/or related DARPA Research which would have the effect of
impacting the work performed by Humabs or payment obligations owed to Humabs under the DARPA Subcontract without prior approval and consent by Humabs. MedImmune shall, where it is reasonably able to do so, consult with Humabs in relation
to any interactions with DARPA which MedImmune reasonable believes may have the effect of impacting the work performed by Humabs or payment obligations owed to Humabs. 

 

	 	2.4	 A new definition shall be added as follows: 

“Klebsiella” means human Klebsiella species of the Enterobacteriaceae family. 

 

	 	2.5	 Section 1.1.97 shall be amended in respect of the Extra Target only, to read as follows:

 “Research Term” means the period from the date of this Amendment until the [***]. 

 

	 	2.6	 Section 1.1.103 shall be amended to read as follows: 

“Extra Target” means Klebsiella. 

  
 Page 2 of 8 

/s/FR  /s/DC 

	 	2.7	 Section 2.4 shall be amended to include the following: 

[***] 
  

	 	2.8	 Pursuant to Section 2.8.2, the Parties hereby agree to add the Extra Target Patents and Extra Target Know-how set forth in Annex 1 hereto. 

  

	 	2.9	 The Parties hereby agree that the provisions of Section 5.23 shall not apply to the Extra Target and
instead the funding for the Additional Research Plan in respect of the Extra Target shall be as provided by the DARPA Subcontract. The milestone payments and deliverables related thereto are attached as Annex III to this Amendment, and will be
incorporated into the DARPA Subcontract. 

  

	 	2.10	 In respect of the Additional Research Plan for the Extra Target only, Section 5.24 shall be amended to
read as follows: 

 Humabs acknowledges and agrees that it shall commit the number of full time employees as set forth in
the DARPA Subcontract to the Additional Research Plan in respect of the Extra Target during the Research Term. 
  

	 	2.11	 In respect of the Extra Target only, an additional sentence shall be added to the end of Section 9.3 as
follows: 

  
 Page 3 of 8 

/s/FR  /s/DC 

 MedImmune shall have the right to disclose Confidential Information of Humabs to DARPA;
provided however, that the information is designated as “Limited Rights” data and, provided further, that MedImmune notifies Humabs prior to any such disclosure of Confidential Information to DARPA to afford Humabs
sufficient time and opportunity to review and determine whether to seek a protective order. 
  

	 	2.12	 Humabs acknowledges that, with respect to the Extra Target, the 2012 Agreement shall at all times be subject to
applicable laws, rules, regulations and/or provisions of the DARPA Agreement and DARPA Subcontract and in the event of conflict between such laws, rules, regulations and/or provisions and the terms of this 2012 Agreement, the relevant laws, rules,
regulations and/or provisions shall control, but only to the extent necessary to enable Humabs to comply with its obligations under the DARPA Subcontract. 

  

	 	2.13	 Pursuant to the DARPA Subcontract [***]. The Parties agree that the provisions contained in the 2012
Agreement which apply to the Second Target and Second Target Products shall equally apply to the Extra Target and any Biologics directed to such Extra Target [***]. 

 

	 	2.14	 Ownership of any and all Intellectual Property (as such terms is defined in the 2012 Agreement) arising from
the activities performed under the Subcontract Agreement shall be owned as set forth in the 2012 Agreement. Should a conflict arise in the interpretation or treatment of any Intellectual Property rights, title or ownership interest, in
whole or in part, as between the 2012 Agreement and the DARPA Subcontract, the DARPA Subcontract shall control. 

  

	 	2.15	 Section 17.4 shall be deleted in its entirety and replaced with the following: 

Assignment. MedImmune shall have the right to assign any of its rights under the 2012 Agreement, as amended herein, to any of its
Affiliates or in connection with a Change of Control without the need for consent from Humabs. Humabs shall have the right to assign any of its rights under this 2012 Agreement, as amended herein, in connection with a Change in Control without
the need for consent from MedImmune so long as such assignment does not materially impact the Parties’ respective rights and obligations under the 2012 Agreement, DARPA Subcontract and/or this Amendment or breach any of the terms of the 2012
Agreement, DARPA Subcontract and/or this Amendment. 

  
 Page 4 of 8 

/s/FR  /s/DC 

 3. Entire Agreement  

 

	 	3.1	 This Amendment, together with the 2012 Agreement and the DARPA Subcontract, constitutes the entire agreement
between the Parties with respect to the subject matter hereto. The 2012 Agreement, together with this Amendment and the DARPA Subcontract, supersedes all prior agreements, whether written or oral, with respect to the subject matter of the 2012
Agreement, as amended. Each Party confirms that it is not relying on any representations, warranties or covenants of the other party except as specifically set out in the 2012 Agreement as amended. Nothing in this Amendment is intended to
limit or exclude any liability for fraud. The Parties hereby agree that subject to the modifications specifically stated in this Amendment, all terms and conditions of the 2012 Agreement shall remain in full force and effect.

 IN WITNESS WHEREOF, THE PARTIES ACKNOWLEDGE AND AGREE THAT THIS AMENDMENT IS MADE AND ENTERED INTO IN MUTUALLY ACCEPTABLE FORM TO BE
EXECUTED AND EFFECTIVE AS OF THE AMENDMENT EFFECTIVE DATE. 
  

							
		  	Signed	  	
		  	For and on behalf of MedImmune, LLC	  	
				
		  	Name:	  	JoAnn Suzich	  	
		  	Position:	  	Vice President, Research	  	
			
		  	Signed         /s/ Filippo Riva	  	
		  	For and on behalf of Humabs BioMed SA	  	
				
		  	Name:	  	Filippo Riva         Davide Corti	  	
		  	Position:	  	CEO & CFO         CSO	  	

  
 Page 5 of 8 

 ANNEX I—EXTRA TARGET PATENTS AND EXTRA TARGET
KNOW-HOW 
 [***] 

  
 Page 6 of 8 

 ANNEX II—ADDITIONAL RESEARCH PLAN 

[***] 

  
 Page 7 of 8 

/s/FR  /s/DC 

 ANNEX III—MILESTONE PAYMENTS AND DELIVERABLES 

[***] 

  
 Page 8 of 8 

/s/FR  /s/DC

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]